Association between serum LDH and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma: supplemental materials

Published: 16 February 2022| Version 1 | DOI: 10.17632/98c99dcvtt.1
Contributors:
Maria Asdourian, Tracey Otto, Ted Jacoby, Nishi Shah, Steven Blum, Kerry Reynolds, Yevgeniy Semenov, Donald Lawrence, Ryan Sullivan, Genevieve Boland, Alexandra-Chloé Villani, Steven Chen

Description

This file details the methodological approach and results of survival analysis using Cox proportional hazards regression modeling to examine the relationship between LDH level and progression-free (PFS) or overall survival (OS) among all patients in our cohort. Results demonstrated that elevated serum LDH at >3 months after ICI initiation was significantly associated with worse PFS (HR: 2.81; p<0.001) and OS (HR: 4.77; p<0.001). There were no significant relationships between PFS or OS when examining LDH level at baseline. These results suggest that having an elevated LDH at the >3 month time point is representative of metastatic burden and may be more of a marker for lack of response to ICIs rather than a predictor of survival outcomes. It is possible that our smaller sample size was insufficiently powered to detect survival outcomes but more appropriate for detecting cutaneous immune-related adverse event (cirAE) outcomes.

Files

Categories

Dermatological Disease, Adverse Event, Melanoma, Lactate Dehydrogenase, Immune Checkpoint Blockade

Licence